Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 978-991 |
| Number of pages | 14 |
| Journal | Annals of the rheumatic diseases |
| Volume | 76 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2017 |
Keywords
- DMARDs (biologic)
- NSAIDs
- Physcial therapy
- Spondyloarthritis
- Treatment
- adalimumab
- analgesic agent
- antiinflammatory agent
- C reactive protein
- certolizumab pegol
- disease modifying antirheumatic drug
- etanercept
- glucocorticoid
- golimumab
- infliximab
- interleukin 17 inhibitor
- methotrexate
- nonsteroid antiinflammatory agent
- paracetamol
- salazosulfapyridine
- secukinumab
- tofacitinib
- tumor necrosis factor inhibitor
- unclassified drug
- antirheumatic agent
- interleukin 17
- tumor necrosis factor
- age distribution
- Ankylosing Spondylitis Disease Activity Score
- arthralgia
- Article
- Bath ankylosing spondylitis disease activity index
- clinical effectiveness
- clinical feature
- disease severity
- doctor patient relation
- drug safety
- drug tolerance
- evidence based medicine
- health care cost
- health care quality
- human
- joint stiffness
- medical decision making
- patient education
- personalized medicine
- practice guideline
- priority journal
- quality of life
- risk benefit analysis
- sacroiliitis
- social participation
- spondylarthritis
- treatment contraindication
- treatment planning
- treatment withdrawal
- antagonists and inhibitors
- drug substitution
- treatment outcome
- Analgesics
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Drug Substitution
- Glucocorticoids
- Humans
- Interleukin-17
- Spondylarthritis
- Treatment Outcome
- Tumor Necrosis Factor-alpha
Access to Document
Fingerprint
Dive into the research topics of '2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of the rheumatic diseases, Vol. 76, No. 6, 2017, p. 978-991.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
AU - Van Der Heijde, D.
AU - Ramiro, S.
AU - Landewé, R.
AU - Baraliakos, X.
AU - Van Den Bosch, F.
AU - Sepriano, A.
AU - Regel, A.
AU - Ciurea, A.
AU - Dagfinrud, H.
AU - Dougados, M.
AU - Van Gaalen, F.
AU - Géher, P.
AU - Van Der Horst-Bruinsma, I.
AU - Inman, R.D.
AU - Jongkees, M.
AU - Kiltz, U.
AU - Kvien, T.K.
AU - Machado, P.M.
AU - Marzo-Ortega, H.
AU - Molto, A.
AU - Navarro-Compàn, V.
AU - Ozgocmen, S.
AU - Pimentel-Santos, F.M.
AU - Reveille, J.
AU - Rudwaleit, M.
AU - Sieper, J.
AU - Sampaio-Barros, P.
AU - Wiek, D.
AU - Braun, J.
N1 - Cited By :50 Export Date: 20 March 2018 CODEN: ARDIA Correspondence Address: Van Der Heijde, D.; Department of Rheumatology, Leiden University Medical Center, PO Box 9600, Netherlands; email: [email protected] Chemicals/CAS: adalimumab, 331731-18-1; C reactive protein, 9007-41-4; certolizumab pegol, 428863-50-7; etanercept, 185243-69-0, 200013-86-1; golimumab, 476181-74-5; infliximab, 170277-31-3; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; paracetamol, 103-90-2; salazosulfapyridine, 599-79-1; secukinumab, 875356-43-7, 875356-44-8; tofacitinib, 477600-75-2, 540737-29-9; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Glucocorticoids; Interleukin-17; Tumor Necrosis Factor-alpha References: Dougados, M., Baeten, D., Spondyloarthritis (2011) Lancet, 377, pp. 2127-2137; Stolwijk, C., Van Tubergen, A., Castillo-Ortiz, J.D., Prevalence of extra-Articular manifestations in patients with ankylosing spondylitis: A systematic review and meta-Analysis (2015) Ann Rheum Dis, 74, pp. 65-73; Van Der Linden, S., Valkenburg, H.A., Cats, A., Evaluation of diagnostic criteria for ankylosing spondylitis (1984) A Proposal for Modification of the New York Criteria. Arthritis Rheum, 27, pp. 361-368; Rudwaleit, M., Ma, K., Sieper, J., The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? (2005) Arthritis Rheum, 52, pp. 1000-1008; Sieper, J., Van Der Heijde, D., Review: Nonradiographic axial spondyloarthritis: New definition of an old disease? (2013) Arthritis Rheum, 65, pp. 543-551; Van Den Berg, R., Lenczner, G., Feydy, A., Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs (2014) Results from the DESIR Cohort. Arthritis Rheumatol, 66, pp. 2403-2411; Sepriano, A., Rudwaleit, M., Sieper, J., Five-year follow-up of radiographic sacroiliitis: Progression as well as improvement? (2016) Ann Rheum Dis, 75, pp. 1262-1263; http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM361563.pdf; http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm361566.pdf; Poddubnyy, D., Rudwaleit, M., Haibel, H., Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis (2011) Ann Rheum Dis, 70, pp. 1369-1374; Deodhar, A., Strand, V., Kay, J., The term non-radiographic axial spondyloarthritis is much more important to classify than to diagnose patients with axial spondyloarthritis (2016) Ann Rheum Dis, 75, pp. 791-794; Davis, J.C., Jr., Van Der Heijde, D., Braun, J., Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial (2003) Arthritis Rheum, 48, pp. 3230-3236; Dougados, M., Van Der Heijde, D., Sieper, J., Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: A multicenter, randomized, double-blind, placebo-controlled trial (2014) Arthritis Rheumatol, 66, pp. 2091-2102; Van Der Heijde, D., Kivitz, A., Schiff, M.H., Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial (2006) Arthritis Rheum, 54, pp. 2136-2146; Sieper, J., Van Der Heijde, D., Dougados, M., Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo-controlled trial (ABILITY-1 (2013) Ann Rheum Dis, 72, pp. 815-822; Inman, R.D., Davis, J.C., Jr., Dv, H., Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial (2008) Arthritis Rheum, 58, pp. 3402-3412; Sieper, J., Van Der Heijde, D., Dougados, M., A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis (2015) Arthritis Rheumatol, 67, pp. 2702-2712; Concept Paper on Clinical Investigation of Medicinal Products for the Treatment of Axial Spondyloarthritis, , http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/04/WC500185187.pdf, European Medicines Agency; Braun, J., Pham, T., Sieper, J., International ASAS consensus statement for the use of anti-Tumour necrosis factor agents in patients with ankylosing spondylitis (2003) Ann Rheum Dis, 62, pp. 817-824; Braun, J., Davis, J., Dougados, M., First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis (2006) Ann Rheum Dis, 65, pp. 316-320; Van Der Heijde, D., Sieper, J., Maksymowych, W.P., Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (2011) Ann Rheum Dis 2010, 70, pp. 905-908; Smolen, J.S., Landewé, R., Breedveld, F.C., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs 2013 update (2014) Ann Rheum Dis, 73, pp. 492-509; Gossec, L., Smolen, J.S., Ramiro, S., European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies 2015 update (2016) Ann Rheum Dis, 75, pp. 499-510; Zochling, J., Van Der Heijde, D., Burgos-Vargas, R., ASAS/EULAR recommendations for the management of ankylosing spondylitis (2006) Ann Rheum Dis, 65, pp. 442-452; Den Van, B.J., Berg, R., Baraliakos, X., Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (2010) Ann Rheum Dis, 2011 (70), pp. 896-904; Baeten, D., Sieper, J., Braun, J., Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis (2015) N Engl J Med, 373, pp. 2534-2548; Sieper, J., Deodhar, A., Marzo-Ortega, H., Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: Results from the MEASURE 2 Study (2016) Ann Rheum Dis, , [Epub ahead of print 31 Aug 2016]; Landewé, R., Braun, J., Deodhar, A., Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study (2014) Ann Rheum Dis, 73, pp. 39-47; Van Der Heijde, D., Aletaha, D., Carmona, L., Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations (2015) Ann Rheum Dis 2014, 74, pp. 8-13; Appraisal of Guidelines for Research & Evaluation II, , http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-And-23-item-Instrument_2009_UPDATE_2013.pdf; Ramiro, S., Sepriano, A., Chatzidionysiou, A., Safety of synthetic and biological DMARDs: A systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis Ann Rheum Dis 2016; Jpt, H., Altman, D.G., (2008) Assessing Risk of Bias in Included Studies, , Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; Hayden, J.A., Côté, P., Bombardier, C., Evaluation of the quality of prognosis studies in systematic reviews (2006) Ann Intern Med, 144, pp. 427-437; Zochling, J., Van Der Heijde, D., Dougados, M., Current evidence for the management of ankylosing spondylitis: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis (2006) Ann Rheum Dis, 65, pp. 423-432; Van Den Berg, R., Baraliakos, X., Braun, J., First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: A systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis (2012) Rheumatology (Oxford), 51, pp. 1388-1396; Baraliakos, X., Van Den Berg, R., Braun, J., Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis (2012) Rheumatology (Oxford), 51, pp. 1378-1387; (2012) Oxford Centre for Evidence-Based Medicine, , http://www.cebm.net/oxford-centre-evidence-based-medicinelevels-evidence-march-2009/, The Oxford 2009 Levels of Evidence (updated in); Smolen, J.S., Van Der Heijde, D., Machold, K.P., Proposal for a new nomenclature of disease-modifying antirheumatic drugs (2014) Ann Rheum Dis, 73, pp. 3-5; Rudwaleit, M., Van Der Heijde, D., Landewé, R., The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis ( part II): Validation and final selection (2009) Ann Rheum Dis, 68, pp. 777-783; Peters, M.J., Symmons, D.P., McCarey, D., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis (2010) Ann Rheum Dis, 69, pp. 325-331; Baillet, A., Gossec, L., Carmona, L., Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: A EULAR initiative (2016) Ann Rheum Dis, 75, pp. 965-973; Van Assen, S., Agmon-Levin, N., Elkayam, O., EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases (2011) Ann Rheum Dis, 70, pp. 414-422; Vander Cruyssen, B., Ribbens, C., Boonen, A., The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice (2007) Ann Rheum Dis, 66, pp. 1072-1077; Van Der Heijde, D., Dijkmans, B., Geusens, P., Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT (2005) Arthritis Rheum, 52, pp. 582-591; Boonen, A., Sieper, J., Van Der Heijde, D., The burden of non-radiographic axial spondyloarthritis (2015) Semin Arthritis Rheum, 44, pp. 556-562; (2001) The International Classification of Functioning Disability and Health, , Geneva World Health Organization; Boonen, A., Braun, J., Van Der Horst, B.I.E., ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): How to classify the impact of AS on functioning and health (2010) Ann Rheum Dis, 69, pp. 102-107; Kiltz, U., Van Der Heijde, D., Boonen, A., Development of a health index in patients with ankylosing spondylitis (ASAS HI): Final result of a global initiative based on the ICF guided by ASAS (2015) Ann Rheum Dis, 74, pp. 830-835; Ramiro, S., Van Der Heijde, D., Van Tubergen, A., Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort (2014) Ann Rheum Dis, 73, pp. 1455-1461; Landewé, R., Dougados, M., Mielants, H., Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine (2009) Ann Rheum Dis, 68, pp. 863-867; Poddubnyy, D., Protopopov, M., Haibel, H., High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: Results from the German SPondyloarthritis Inception Cohort (2016) Ann Rheum Dis, 75, pp. 2114-2118; Van Der Heijde, D., Joshi, A., Pangan, A.L., ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis (2016) Rheumatology (Oxford), 55, pp. 80-88; Westhovens, R., Annemans, L., Costs of drugs for treatment of rheumatic diseases (2016) RMD Open, 2, p. e000259; Sieper, J., Rudwaleit, M., Baraliakos, X., The assessment of spondyloarthritis international society (asas) handbook: A guide to assess spondyloarthritis (2009) Ann Rheum Dis, 68, pp. ii1-44; Van Der Heijde, D., Lie, E., Kvien, T.K., ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis (2009) Ann Rheum Dis, 68, pp. 1811-1818; Van Der Heijde, D., Maksymowych, W., Landewé, R., Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12-week magnetic resonance imaging results of RAPID-AxSpA study (2013) Ann Rheum Dis, 72, p. 515; Navarro-Compán, V., Ramiro, S., Landewé, R., Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort (2016) Ann Rheum Dis, 75, pp. 874-878; Machado, P., Landewé, R.B., Braun, J., MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor (2012) Ann Rheum Dis, 71, pp. 2002-2005; Van Der Heijde, D., Sieper, J., Maksymowych, W.P., Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis (2014) Arthritis Rheumatol, 66, pp. 667-673; Kiltz, U., Baraliakos, X., Karakostas, P., The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: A cohort study (2012) Ann Rheum Dis, 71, pp. 1207-1211; Zangi, H.A., Ndosi, M., Adams, J., EULAR recommendations for patient education for people with inflammatory arthritis (2015) Ann Rheum Dis, 74, pp. 954-962; Sudre, A., Figuereido, I.T., Lukas, C., On the impact of a dedicated educational program for ankylosing spondylitis: Effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study (2012) Joint Bone Spine, 79, pp. 99-100; Candelas, G., Villaverde, V., García, S., Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: A systematic literature review (2016) Rheumatol Int, 36, pp. 1493-1506; Dagfinrud, H., Kvien, T.K., Hagen, K.B., Physiotherapy interventions for ankylosing spondylitis (2008) Cochrane Database Syst Rev, 1, p. CD002822; Poddubnyy, D., Haibel, H., Listing, J., Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis (2012) Arthritis Rheum, 64, pp. 1388-1398; Ramiro, S., Landewé, R., Van Tubergen, A., Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: A longitudinal analysis (2015) RMD Open, 1, p. e000153; Chung, H.Y., Machado, P., Van Der Heijde, D., Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: Results from the DESIR cohort (2012) Ann Rheum Dis, 71, pp. 809-816; Sieper, J., Lenaerts, J., Wollenhaupt, J., Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: Results from the double-blind, placebo-controlled INFAST study, Part 1 (2014) Ann Rheum Dis, 73, pp. 101-107; Bakland, G., Gran, J.T., Nossent, J.C., Increased mortality in ankylosing spondylitis is related to disease activity (2011) Ann Rheum Dis, 70, pp. 1921-1925; Haroon, N.N., Paterson, J.M., Li, P., Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: A population-based study (2015) Ann Intern Med, 163, pp. 409-416; Wanders, A., Dv, H., Landewé, R., Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial (2005) Arthritis Rheum, 52, pp. 1756-1765; Kroon, F., Landewé, R., Dougados, M., Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis (2012) Ann Rheum Dis, 71, pp. 1623-1629; Poddubnyy, D., Rudwaleit, M., Haibel, H., Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort (2012) Ann Rheum Dis, 71, pp. 1616-1622; Sieper, J., Listing, J., Poddubnyy, D., Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: Results from a randomised multicentre trial (ENRADAS (2016) Ann Rheum Dis, 75, pp. 1438-1443; Van Der Heijde, D., Machado, P., Braun, J., MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: A multilevel analysis in patients with ankylosing spondylitis (2012) Ann Rheum Dis, 71, pp. 369-373; Machado, P.M., Baraliakos, X., Van Der Heijde, D., MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: A multilevel longitudinal analysis in patients with ankylosing spondylitis (2016) Ann Rheum Dis, 75, pp. 1486-1493; Baraliakos, X., Heldmann, F., Callhoff, J., Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-Term observational study using MRI and conventional radiography (2014) Ann Rheum Dis, 73, pp. 1819-1825; Maksymowych, W.P., Chiowchanwisawakit, P., Clare, T., Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: Evidence of a relationship between inflammation and new bone formation (2009) Arthritis Rheum, 60, pp. 93-102; Haibel, H., Fendler, C., Listing, J., Efficacy of oral prednisolone in active ankylosing spondylitis: Results of a double-blind, randomised, placebo-controlled short-Term trial (2014) Ann Rheum Dis, 73, pp. 243-246; Chen, J., Liu, C., Sulfasalazine for ankylosing spondylitis (2005) Cochrane Database Syst Rev, 2, p. CD004800; Chen, J., Liu, C., Lin, J., Methotrexate for ankylosing spondylitis (2006) Cochrane Database Syst Rev, 4, p. CD004524; Haibel, H., Brandt, H.C., Song, I.H., No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: A 16-week open-label trial (2007) Ann Rheum Dis, 66, pp. 419-421; Arends, S., Brouwer, E., Van Der Veer, E., Baseline predictors of response and discontinuation of tumor necrosis factor-Alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study (2011) Arthritis Res Ther, 13, p. R94; Glintborg, B., Ostergaard, M., Krogh, N.S., Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-Tumour necrosis factor: Results from 8 years surveillance in the Danish nationwide DANBIO registry (2010) Ann Rheum Dis, 69, pp. 2002-2008; Rudwaleit, M., Schwarzlose, S., Hilgert, E.S., MRI in predicting a major clinical response to anti-Tumour necrosis factor treatment in ankylosing spondylitis (2008) Ann Rheum Dis, 67, pp. 1276-1281; Machado, P., Landewé, R., Lie, E., Ankylosing Spondylitis Disease Activity Score (ASDAS): Defining cut-off values for disease activity states and improvement scores (2011) Ann Rheum Dis, 70, pp. 47-53; Lukas, C., Landewé, R., Sieper, J., Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis (2009) Ann Rheum Dis, 68, pp. 18-24; Fagerli, K.M., Lie, E., Van Der Heijde, D., Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: Comparison of ASDAS and BASDAI eligibility criteria (2012) Rheumatology (Oxford), 51, pp. 1479-1483; Vastesaeger, N., Cruyssen, B.V., Mulero, J., ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy (2014) Reumatol Clin, 10, pp. 204-209; Hueber, W., Sands, B.E., Lewitzky, S., Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohns disease: Unexpected results of a randomised, double-blind placebo-controlled trial (2012) Gut, 61, pp. 1693-1700; Langley, R.G., Elewski, B.E., Lebwohl, M., Secukinumab in plaque psoriasis-results of two phase 3 trials (2014) N Engl J Med, 371, pp. 326-338; Braun, J., Baraliakos, X., Listing, J., Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-Tumor necrosis factor agents infliximab and etanercept (2005) Arthritis Rheum, 52, pp. 2447-2451; Van Denderen, J.C., Visman, I.M., Nurmohamed, M.T., Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis (2014) J Rheumatol, 41, pp. 1843-1848; Rudwaleit, M., Rosenbaum, J.T., Landewé, R., Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis (2016) Arthritis Care Res (Hoboken, 68, pp. 838-844; Sieper, J., Koenig, A., Baumgartner, S., Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials (2010) Ann Rheum Dis, 69, pp. 226-229; Foster, C.S., Tufail, F., Waheed, N.K., Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate (2003) Arch Ophthalmol, 121, pp. 437-440; Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Maintenance infliximab for Crohns disease: The ACCENT i randomised trial (2002) Lancet, 359, pp. 1541-1549; Sandborn, W.J., Hanauer, S.B., Rutgeerts, P., Adalimumab for maintenance treatment of Crohns disease: Results of the CLASSIC II trial (2007) Gut, 56, pp. 1232-1239; Sandborn, W.J., Feagan, B.G., Stoinov, S., Certolizumab pegol for the treatment of Crohns disease (2007) N Engl J Med, 357, pp. 228-238; Song, I.H., Appel, H., Haibel, H., New onset of Crohns disease during treatment of active ankylosing spondylitis with etanercept (2008) J Rheumatol, 35, pp. 532-536; Adedokun, O.J., Xu, Z., Marano, C.W., Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-To-severely active ulcerative colitis: Results from phase 2/3 PURSUIT induction and maintenance studies (2016) J Crohns Colitis; Lie, E., Van Der Heijde, D., Uhlig, T., Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: Data from the NOR-DMARD register (2011) Ann Rheum Dis, 70, pp. 157-163; Yates, M., Hamilton, L.E., Elender, F., Is Etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial (2015) J Rheumatol, 42, pp. 1177-1185; Cantini, F., Niccoli, L., Cassarà, E., Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: A randomized, prospective, long-Term, follow-up study (2013) Biologics, 7, pp. 1-6; Song, I.H., Althoff, C.E., Haibel, H., Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial (2012) Ann Rheum Dis, 71, pp. 1212-1215; Haibel, H., Heldmann, F., Braun, J., Long-Term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare (2013) Arthritis Rheum, 65, pp. 2211-2213; Vander Cruyssen, B., Muñoz-Gomariz, E., Font, P., Hip involvement in ankylosing spondylitis: Epidemiology and risk factors associated with hip replacement surgery (2010) Rheumatology (Oxford, 49, pp. 73-81; Van Royen, B.J., De Gast, A., Lumbar osteotomy for correction of thoracolumbar kyphotic deformity in ankylosing spondylitis (1999) A Structured Review of Three Methods of Treatment. Ann Rheum Dis, 58, pp. 399-406; Westerveld, L.A., Verlaan, J.J., Oner, F.C., Spinal fractures in patients with ankylosing spinal disorders: A systematic review of the literature on treatment, neurological status and complications (2009) Eur Spine J, 18, pp. 145-156; Mandl, P., Navarro-Compán, V., Terslev, L., EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice (2015) Ann Rheum Dis, 74, pp. 1327-1339; Kesselheim, A.S., Avorn, J., Sarpatwari, A., The high cost of prescription drugs in the United States: Origins and prospects for reform (2016) JAMA, 316, pp. 858-871; Ward, M.M., Deodhar, A., Akl, E.A., Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (2016) Arthritis Care Res (Hoboken), 68, pp. 151-166. , American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015
PY - 2017
Y1 - 2017
N2 - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-To-date guidance on the management of patients with axSpA. © Published by the BMJ Publishing Group Limited.
AB - To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-To-date guidance on the management of patients with axSpA. © Published by the BMJ Publishing Group Limited.
KW - DMARDs (biologic)
KW - NSAIDs
KW - Physcial therapy
KW - Spondyloarthritis
KW - Treatment
KW - adalimumab
KW - analgesic agent
KW - antiinflammatory agent
KW - C reactive protein
KW - certolizumab pegol
KW - disease modifying antirheumatic drug
KW - etanercept
KW - glucocorticoid
KW - golimumab
KW - infliximab
KW - interleukin 17 inhibitor
KW - methotrexate
KW - nonsteroid antiinflammatory agent
KW - paracetamol
KW - salazosulfapyridine
KW - secukinumab
KW - tofacitinib
KW - tumor necrosis factor inhibitor
KW - unclassified drug
KW - antirheumatic agent
KW - interleukin 17
KW - tumor necrosis factor
KW - age distribution
KW - Ankylosing Spondylitis Disease Activity Score
KW - arthralgia
KW - Article
KW - Bath ankylosing spondylitis disease activity index
KW - clinical effectiveness
KW - clinical feature
KW - disease severity
KW - doctor patient relation
KW - drug safety
KW - drug tolerance
KW - evidence based medicine
KW - health care cost
KW - health care quality
KW - human
KW - joint stiffness
KW - medical decision making
KW - patient education
KW - personalized medicine
KW - practice guideline
KW - priority journal
KW - quality of life
KW - risk benefit analysis
KW - sacroiliitis
KW - social participation
KW - spondylarthritis
KW - treatment contraindication
KW - treatment planning
KW - treatment withdrawal
KW - antagonists and inhibitors
KW - drug substitution
KW - treatment outcome
KW - Analgesics
KW - Anti-Inflammatory Agents, Non-Steroidal
KW - Antirheumatic Agents
KW - Drug Substitution
KW - Glucocorticoids
KW - Humans
KW - Interleukin-17
KW - Spondylarthritis
KW - Treatment Outcome
KW - Tumor Necrosis Factor-alpha
U2 - 10.1136/annrheumdis-2016-210770
DO - 10.1136/annrheumdis-2016-210770
M3 - Article
SN - 0003-4967
VL - 76
SP - 978
EP - 991
JO - Annals of the rheumatic diseases
JF - Annals of the rheumatic diseases
IS - 6
ER -